Moderna's stock jumps after biotech raises sales outlook

Morningstar · 2026-11-06 12:48 UTC

The company lifted its revenue outlook for the year, saying it now expects revenue to grow as much as 25% in 2026

By Jaimy Lee

The company lifted its revenue outlook for the year, saying it now expects revenue to grow as much as 25% in 2026

Moderna's top-selling product is still Spikevax, its mRNA-based COVID-19 vaccine. (Photo by JOSEPH PREZIOSO/AFP via Getty Images)